Czech Academy institute bridging organic chemistry with drug discovery, gene therapy tools, and emerging quantum sensing applications.
IOCB Prague is one of Central Europe's leading research institutes in organic chemistry and biochemistry, housed within the Czech Academy of Sciences. They develop chemical tools for biological discovery — from designing small-molecule drug candidates and glycobiology probes to engineering nucleic acid therapies and photocatalytic methods. Their work bridges synthetic chemistry with biomedical applications, producing both fundamental knowledge and compounds with therapeutic or materials-science potential. They also contribute to pan-European life science data infrastructure through the ELIXIR network.
Coordinated SWEETOOLS (glycobiology tools, largest grant at EUR 1.4M), ProTeCT (proteasome inhibitors for trichomoniasis), and KavaTarget (molecular targets of kavalactones using iBodies).
Participated in ClickGene (click chemistry for gene therapies) and NATURE-ETN (CRISPR, gene editing, immunotherapy, epigenetics).
Coordinated PhotoRedOx (transition metal photoredox mechanisms, C-H activation) and participated in HEL4CHIROLED (chiral helical systems for OLEDs).
Coordinated ChemiQS (2022), their most recent project, combining chemistry with nitrogen-vacancy diamond probes and polymer interfaces.
Participated in ELIXIR-EXCELERATE and ELIXIR-CONVERGE, contributing to FAIR data management and bioinformatics infrastructure across Europe.
In their early H2020 period (2015–2018), IOCB Prague focused on bioinformatics infrastructure (ELIXIR), click chemistry for gene therapy, and glycobiology tool development — broadly foundational work in chemical biology and data services. From 2019 onward, their portfolio shifted toward more targeted biomedical applications (CRISPR, gene editing, immunotherapy) while simultaneously branching into physical chemistry domains like photoredox catalysis and quantum sensing. This signals an institute expanding from its organic chemistry core into interdisciplinary territory where chemistry meets physics and advanced therapeutics.
IOCB Prague is diversifying from traditional organic synthesis toward frontier applications in quantum sensing, photocatalysis, and nucleic acid therapeutics — positioning themselves at chemistry's interface with physics and medicine.
IOCB Prague operates as a balanced coordinator-participant, leading exactly half their H2020 projects (5 of 10). Their coordinator roles are concentrated in focused MSCA fellowships and an ERC Starting Grant, suggesting they attract talented individual researchers who build projects around IOCB's infrastructure. As a participant, they join larger training networks (MSCA-ITN) and research infrastructure consortia (ELIXIR), contributing specialized chemistry expertise. With 107 unique partners across 26 countries, they maintain a wide but non-repetitive network — more of a connector than a closed-circle collaborator.
Extensive European network spanning 107 unique partners across 26 countries, reflecting participation in large training networks (MSCA-ITN) and pan-European infrastructure projects (ELIXIR). Their reach is genuinely continental rather than regionally concentrated.
IOCB Prague is one of the few Central European institutes that combines deep organic chemistry expertise with active participation in both biomedical applications and physical chemistry frontiers. Their ability to coordinate ERC and MSCA projects demonstrates they attract top individual talent, while their ELIXIR involvement shows commitment to open data infrastructure — a rare combination of bench chemistry excellence and data-sharing maturity. For consortium builders, they offer a credible Czech partner with genuine research depth, not just a flag-of-convenience participation.
